Johnson & Johnson delivered solid Q4 results with $24.6B in revenue and $5.1B in net income. EPS reached $2.10 ($2.46 adj.), supported by strong performance in its Innovative Medicine and MedTech businesses.

Johnson & Johnson saw a sharp rise in net income and strong sales growth, particularly across its Innovative Medicine and MedTech segments, leading to an upward revision of its 2025 full-year sales guidance.

Johnson & Johnson delivered strong Q2 2025 results, with revenue growth driven by MedTech and oncology products. The company reported higher net income and raised its full-year sales and EPS guidance.

Johnson & Johnson delivered solid financial performance in Q1 2025, driven by growth across key product lines in Innovative Medicine and MedTech. Net income surged due to the reversal of special charges, and the company advanced its innovation strategy with key regulatory approvals and clinical trial initiations.

Johnson & Johnson reported a 5.3% increase in Q4 sales, reaching $22.5 billion. EPS was reported at $1.41 and adjusted EPS at $2.04, which included $(0.22) impact from acquired IPR&D charges related to the V-Wave acquisition. The company issued guidance for 2025, projecting operational sales growth of 2.5% - 3.5% and adjusted operational EPS of $10.75 - $10.95.

Johnson & Johnson's Q3 2024 results showed a 5.2% increase in reported sales to $22.5 billion. EPS decreased by 34.3% to $1.11, while adjusted EPS decreased by 9.0% to $2.42. The company has increased its full-year 2024 operational sales guidance and updated its adjusted operational EPS guidance.

Johnson & Johnson reported a 4.3% increase in sales to $22.4 billion and an EPS of $1.93, which decreased by 5.9%. Adjusted EPS increased by 10.2% to $2.82. The company has increased its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical and updated its full-year 2024 adjusted operational EPS guidance to reflect improved performance.

Johnson & Johnson reported a solid first quarter in 2024, with sales growth of 2.3% to $21.4 billion and adjusted EPS growth of 12.4% to $2.71. The company is increasing its full-year 2024 operational sales and adjusted operational EPS guidance.

Johnson & Johnson reported a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, and a 39.3% increase in EPS to $1.70 and adjusted EPS of $2.29 increasing by 11.7%. The company re-confirmed its 2024 guidance with operational sales growth of 5.0% - 6.0% and adjusted operational EPS of $10.55 - $10.75.

Johnson & Johnson's Q3 2023 results showed a sales growth of 6.8% reaching $21.4 billion and an EPS of $1.69, which increased by 4.3%. The adjusted EPS was $2.66, reflecting a 19.3% increase. The company is increasing its 2023 full-year guidance midpoints for sales and adjusted EPS.

Johnson & Johnson reported a strong second quarter with sales growth of 6.3% to $25.5 billion and EPS of $1.96, increasing by 8.9%. The company is increasing its full-year guidance for adjusted operational sales and adjusted operational EPS, and plans to split off Kenvue shares through an exchange offer.

Johnson & Johnson reported a total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%. Earnings per share increased by 3.0% to $1.37, and adjusted earnings per share increased by 18.2% to $2.60. The company is increasing its 2021 full-year guidance.

Johnson & Johnson reported strong second-quarter results with sales growth of 27.1% to $23.3 billion and EPS of $2.35, a 72.8% increase. The company is increasing its 2021 full-year guidance for sales and EPS.

Johnson & Johnson's first-quarter sales reached $22.3 billion, reflecting a 7.9% growth. The company's EPS increased by 6.9% to $2.32, with adjusted EPS rising by 12.6% to $2.59. The company also increased its full-year guidance for adjusted operational sales and EPS growth.

Johnson & Johnson reported Q4 2020 sales of $22.5 billion, reflecting growth of 8.3%. The company's EPS was $0.65, a decrease of 56.7%, while adjusted EPS was $1.86, a decrease of 1.1%. Full-year sales were $82.6 billion, and the company provided 2021 guidance of adjusted operational sales growth of 8.8% and adjusted operational EPS growth of 16.4%.

Johnson & Johnson reported Q3 2020 results with sales of $21.1 billion, reflecting a 1.7% increase. EPS increased by 101.5% to $1.33, and adjusted EPS increased by 3.8% to $2.20. The company is increasing its full-year guidance for reported sales by $1.0 billion and adjusted EPS by $0.15.

Johnson & Johnson reported a decrease in sales and EPS for the second quarter of 2020, primarily due to the negative impact of the COVID-19 pandemic. However, the Pharmaceutical business showed continued growth.

Johnson & Johnson reported a strong first quarter with sales of $20.7 billion, reflecting a 3.3% increase. EPS increased by 56.1% to $2.17, and adjusted EPS increased by 9.5% to $2.30. The company also announced a 6.3% increase in the quarterly dividend.

Johnson & Johnson announced its Q4 2019 results, reporting sales of $20.7 billion and EPS of $1.50. The company's performance was driven by its Pharmaceutical business, Medical Devices business, and Consumer business.